Aviragen Therapeutics slammed again by its second trial failure in days, this time for their lead drug
In back-to-back setbacks, Aviragen Therapeutics $AVIR says that its lead drug vapendavir flunked a Phase IIb in moderate to severe asthmatics with a rhinovirus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
